Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Adalimumab biosimilar: Phase III started

    Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Product: Adalimumab biosimilar Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Human …

    Published on 5/25/2015
  • AYX1: Completed Phase II enrollment

    Adynxx Inc., San Francisco, Calif. Product: AYX1 Business: Neurology Molecular target: Early growth response 1 (EGR1) Description: Small synthetic dsDNA inhibitor of early growth response 1 (EGR1) Indication: Prevent …

    Published on 5/25/2015
  • BCX7353: Phase I started

    BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. Product: BCX7353 Business: Inflammation Molecular target: Kallikrein Description: Second-generation kallikrein inhibitor Indication: Prevent attacks in patients …

    Published on 5/25/2015
  • Birinapant: Phase I halted

    TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Birinapant (formerly TL32711) Business: Infectious Molecular target: Inhibitor of apoptosis (IAP) Description: Small molecule peptidomimetic of …

    Published on 5/25/2015
  • BNC210: Phase II started

    Bionomics Ltd. (ASX:BNO; OTCQX:BMICY), Thebarton, Australia Product: BNC210 Business: Neurology Molecular target: Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Description: Small molecule anxiolytic Indication: …

    Published on 5/25/2015
  • Cannabidiol: Phase I/II started

    Insys Therapeutics Inc. (NASDAQ:INSY), Phoenix, Ariz. Product: Cannabidiol (CBD) oral solution Business: Neurology Molecular target: NA Description: Oral solution of synthetic cannabidiol Indication: Treat treatment-…

    Published on 5/25/2015
  • ChAd3-EBO-Z: Phase I started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: ChAd3-EBO-Z Business: Infectious Molecular target: NA Description: Recombinant chimpanzee adenovirus type 3 (ChAd3) vector vaccine carrying the wild-type …

    Published on 5/25/2015
  • CM-AT: Phase III started

    Curemark LLC, Rye, N.Y. Product: CM-AT Business: Neurology Molecular target: NA Description: Powder formulation of an undisclosed enzyme that is released in the small intestine to aid in protein digestion Indication: …

    Published on 5/25/2015
  • Cogenzia gentamicin topical: Phase III started

    Innocoll AG (NASDAQ:INNL), Athlone, Ireland Product: Cogenzia gentamicin topical (CollaRx) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Topical bioresorbable collagen sponge with gentamicin …

    Published on 5/25/2015
  • DCR-MYC: Phase I ongoing

    Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA), Watertown, Mass. Product: DCR-MYC Business: Cancer Molecular target: v-myc myelocytomatosis viral oncogene homolog (MYC) (c-Myc) Description: Dicer substrate short interfering…

    Published on 5/25/2015
  • GMI-1271: Phase I/II started

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Product: GMI-1271 Business: Cancer Molecular target: E selectin (SELE) (CD62E) Description: Inhibitor of E selectin (SELE; CD62E) Indication: Treat acute myelogenous …

    Published on 5/25/2015
  • GZ/SAR402671: Phase IIa started

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: GZ/SAR402671, GZ402671 Business: Endocrine/Metabolic Molecular target: Glucosylceramide synthase (GCS) Description: Glucosylceramide synthase (GCS) inhibitor …

    Published on 5/25/2015
  • INVAC1: Phase I started

    Invectys S.A., Paris, France Product: INVAC1, INVAC-1 Business: Cancer Molecular target: Telomerase reverse transcriptase (TERT) Description: Therapeutic DNA vaccine carrying the telomerase reverse transcriptase (TERT) …

    Published on 5/25/2015
  • Ixazomib: Phase III started

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Ixazomib (MLN9708) Business: Cancer Molecular target: Proteasome Description: Oral proteasome inhibitor Indication: Maintenance treatment of newly …

    Published on 5/25/2015
  • Lasmiditan: Phase III started

    CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD), Durham, N.C. Product: Lasmiditan (COL-144) Business: Neurology Molecular target: Serotonin (5-HT1F) receptor Description: Selective agonist of serotonin (5-HT1F) receptor …

    Published on 5/25/2015
  • MVA EBOZ: Phase I started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: MVA EBOZ Business: Infectious Molecular target: NA Description: Modified vaccinia Ankara (MVA) virus vector Indication: Prevent Ebola virus infection …

    Published on 5/25/2015
  • Niraparib: Completed Phase III enrollment

    Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Niraparib (MK-4827) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Oral poly(…

    Published on 5/25/2015
  • Niraparib: Phase II started

    Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Niraparib (MK-4827) Business: Cancer Molecular target: Poly(ADP-ribose) polymerase (PARP) Description: Oral poly(…

    Published on 5/25/2015
  • Obeticholic acid: Phase III start

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), New York, N.Y. Product: Obeticholic acid (OCA) (DSP-1747) (formerly INT-747, 6ECDCA) Business: Hepatic Molecular target: Farnesoid X receptor (FXR) (NR1H4) Description: Oral…

    Published on 5/25/2015
  • Pembrolizumab: Phase II started

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Pembrolizumab (Keytruda) (MK-3475) (formerly lambrolizumab) Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: …

    Published on 5/25/2015
  • Pradaxa dabigatran etexilate: Phase IV started

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Pradaxa dabigatran etexilate Business: Cardiovascular Molecular target: Thrombin (Factor IIa) (F2) Description: Direct oral thrombin inhibitor Indication: …

    Published on 5/25/2015
  • RenaSure: Clinical trial started

    CareDx Inc. (NASDAQ:CDNA), Brisbane, Calif. Product: RenaSure Business: Diagnostic Molecular target: DNA Description: Detects circulating cell-free DNA Indication: Diagnose acute rejection after kidney transplantation …

    Published on 5/25/2015
  • RT001: Completed Phase II enrollment

    Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Product: RT001 Business: Dermatology Molecular target: NA Description: Topical gel formulation of botulinum neurotoxin type A Indication: Treat lateral canthal …

    Published on 5/25/2015
  • RT002: Completed Phase II enrollment

    Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Product: RT002 Business: Dermatology Molecular target: NA Description: Injectable botulinum toxin type A that uses TransMTS peptide technology Indication: Treat …

    Published on 5/25/2015
  • SynCon DNA HBV vaccine: Phase I started

    Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: SynCon DNA HBV vaccine (INO-1800) Business: Infectious Molecular target: NA Description: Synthetic DNA …

    Published on 5/25/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993